The case for an HIV cure and how to get there

M Dybul, T Attoye, S Baptiste, P Cherutich, F Dabis… - The Lancet …, 2021 - thelancet.com
In light of the increasing global burden of new HIV infections, growing financial
requirements, and shifting funding landscape, the global health community must accelerate …

Defensins: defenders of human reproductive health

YJ Zhai, Y Feng, X Ma, F Ma - Human reproduction update, 2023 - academic.oup.com
BACKGROUND Reproductive tract infection is an important factor leading to male and
female infertility. Among female infertility factors, microbial and viral infections are the main …

Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: a systematic literature …

S Kanters, M Vitoria, M Zoratti, M Doherty… - …, 2020 - thelancet.com
Abstract Background To inform World Health Organization (WHO) global guidelines, we
updated and expanded the evidence base to assess the comparative efficacy, tolerability …

Infectious RNA: human immunodeficiency virus (HIV) biology, therapeutic intervention, and the quest for a vaccine

Y van Heuvel, S Schatz, JF Rosengarten, J Stitz - Toxins, 2022 - mdpi.com
Different mechanisms mediate the toxicity of RNA. Genomic retroviral mRNA hijacks infected
host cell factors to enable virus replication. The viral genomic RNA of the human …

[HTML][HTML] Therapeutic potentials of CRISPR-Cas genome editing technology in human viral infections

S Najafi, SC Tan, S Aghamiri, P Raee… - Biomedicine & …, 2022 - Elsevier
Viral infections are a common cause of morbidity worldwide. The emergence of Coronavirus
Disease 2019 (COVID-19) has led to more attention to viral infections and finding novel …

Challenges of HIV diagnosis and management in the context of pre‐exposure prophylaxis (PrEP), post‐exposure prophylaxis (PEP), test and start and acute HIV …

T Elliott, EJ Sanders, M Doherty… - African Journal of …, 2019 - journals.lww.com
Introduction: Knowledge of HIV status relies on accurate HIV testing, and is the first step
towards access to HIV treatment and prevention programmes. Globally, HIV-status …

Phylogenies in ART: HIV reservoirs, HIV latency and drug resistance

A Bandera, A Gori, M Clerici, M Sironi - Current opinion in pharmacology, 2019 - Elsevier
Highlights•During ART, HIV persists latently in several cell types and tissues.•Proliferation of
latently infected cells is likely responsible for residual viremia.•DRMs do not appear during …

HIV virological non-suppression and its associated factors in children on antiretroviral therapy at a major treatment centre in Southern Ghana: a cross-sectional study

AKA Afrane, BQ Goka, L Renner, AE Yawson… - BMC infectious …, 2021 - Springer
Background Children living with human immunodeficiency virus (HIV) infection require
lifelong effective antiretroviral therapy (ART). The goal of ART in HIV-infected persons is …

Clinically relevant thresholds for ultrasensitive HIV drug resistance testing: a multi-country nested case-control study

SC Inzaule, RL Hamers, M Noguera-Julian… - The Lancet …, 2018 - thelancet.com
Background Implementation of ultrasensitive HIV drug resistance tests for routine clinical
use is hampered by uncertainty about the clinical relevance of drug-resistant minority …

Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial

PDJ Bollen, CL Moore, HA Mujuru, S Makumbi… - The Lancet …, 2020 - thelancet.com
Background Paediatric dolutegravir doses approved by stringent regulatory authorities
(SRAs) for children weighing 20 kg to less than 40 kg until recently required 25 mg and 10 …